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Poster Session I S293NPM1mut; whereas 65% of pts with CD25+ AML had FLT3-ITD-
mut (p5 0.0012). The total of 24 (53%) pts received stem cell trans-
plantation (SCT), 9 (38%) of those were CD25+. Median time from
diagnosis to SCT was 4 months (2-7). At the time of SCT 5 (21%)
CD25+ pts were in CR1 and 4 (17%) were in CR2 or had refractory
disease compared to 14 (58%) CD25- pts in CR1 and 1 (4%) pt had
relapse (p 5 0.047). The RFS was significantly inferior in CD25+
AML pts compared with CD25- pts (6-month; 26% vs 79%; p 5
0.0003). This did not translate into a statistical difference in OS
(1-year; 43% vs 65%; p5 ns). CD25+ pts who received SCThad sig-
nificantly superior 1-year OS (63%) vs CD25+ pts who did not un-
dergo SCT (0%; p 5 0.0098).
In our experience, treatment with SCT appeared to eliminate the
negative impact of CD25 expression. Prospective validation of the
prognostic impact of CD25 in AML is warranted.240
A NOVEL RE-INDUCTION THERAPY CLOFARABINE, CYCLOPHOSPHA-
MIDE, BORTEZOMIB, DEXAMETHASONE, ETOPOSIDE (CCBDE) FOR RE-
LAPSED AND REFRACTORY ALL
Morris, C.L., Morris, J., Brown, B., Bedros, A. Loma Linda University
Medical Center, Loma Linda, CA
Background: Despite advances in treatment of pediatric leukemias,
the prognosis with recurrent disease remains poor. Transplantation
is the treatment of choice for relapses within a year of completing
therapy. In order for transplantation to be successful, the patient
must be in a solid remission.
Methods:We treated 7 pediatric patients (age 1-16 years, median 9)
with relapse ALL that failed standard induction therapy(s). Patients
received clofarabine (40mg/m2/day) days 2 to 6, cyclophosphamide
(400mg/m2/day) days 2-6, bortezomib (1.1mg/m2/day) days 1, 4, 8,
11, Dexamethasone (20mg/m2/day) days 1-6, 8, 11, etoposide
(150mg/m2/day) days 2-6 (CCBDE).
Results: 5/7 patients (71%) achieved a CR after 1 (4) or 2 (1) courses
of CCBDE. All patients had failed 1-4 cycles of standard induction
chemotherapy prior to attempting CCBDE: 2 patients received
COG AALL01P2 plus clofarabine-cyclophosphamide-etoposide in
1, 2 COG ADVL04P2 plus mitozantrone-cytarabine in 1, 2 induc-
tion failures on COG AALL0232 and COG AALL0631, and 1
post-BMT relapse with history of poor response to AALLO1P2.
Two patients had relapsed 3 and 6months after SCT.Despite exten-
sive prior therapy marrow recovery after 1 cycle of CCBDE was
prompt (18-20 days) in non-transplant patients and 40-50 days for
post-SCT.Minimal residual disease (MRD)was\1025 in 4 of the re-
sponders. Three patients had unrelated donor SCT’s. Two died of
toxicity, and one survives 22 months after SCT. Two patients are
in remission awaiting transplant, one has been in continuous remis-
sionwith negativeMRD for 1 yearwithout additional chemotherapy.
Two patients did not respond to CCBDE; 1 had received a prior clo-
farabine regimen and 1 achieved remission with VPLD plus borteza-
mib and went on to a second SCT but relapsed 9 months later.
Conclusion: CCBDE regimen is a novel promising re-induction
chemotherapy regimen for relapsed and refractory ALL. Given the
extensive prior therapy these patients had received the regimen was
well tolerated. Among responders marrow recovery was prompt
for non-transplant patients but more delayed in early post transplant
patients, in this small series. Most responders (4/5) had extremely
deep remissions and none of these have relapsed while awaiting
transplant. We continue to investigate the efficacy of this regimen
and consider the addition of other agents with non-overlapping tox-
icities to improve its effectiveness.241
CLOFARABINE FOR CYTOREDUCTION PRIOR TO ALLOGENEIC TRANS-
PLANT CONDITIONING FOR REFRACTORY ACUTE MYELOGENOUS
LEUKEMIA
Jeyakumar, D., Sprague, K., Miller, K.B., Klein, A., Klingemann, H.
Tufts Medical Center, Boston, MA
Treatment of primary refractory and relapsed refractory AML is
unclear. We report a retrospective analysis of all patients whoreceived clofarabine for refractory AML immediately prior to alloge-
neic stem cell transplantation between 2006 and 2011. Eleven pa-
tients with refractory AML received clofarabine 40 mg/m2 with or
without cytarabine 100mg/m2 prior to AlloSCT. Nine patients
had primary refractory disease, 2 were in first relapse. Median age
was 62. Three patients had de novo AML, 7 prior MDS, 1 prior P.
Vera. One patient had a prior autologous SCT. Cytoreduction
with\10% marrow blasts was achieved in 44%. Two patients died
prior to transplant due to infection. At time of transplant, 6 patients
(66%) had infectious complications. Three patients (33%) had
documented bacteremia prior to transplant. Of the 9 patients who
proceeded to AlloSCT, 6 received RIC with extracorporeal photo-
pheresis for 2 days, Pentostatin 4mg/m2 x 2 days and 600 cGy frac-
tionated TBI. Three patients received myeloablative conditioning: 2
with Cytoxan/TBI 1200 cGy, 1 with Busulfan/Cytoxan. Grade I-II
hyperbilirubinemia and Grade I-II transaminitis were documented
in 4 patients (44%) and 5 patients (55%) after clofarabine prior to
transplant, respectively. Grade I aGvHD occurred in 5 patients
(55%) and grade II aGvHD in 2 patients (22%). No patient devel-
oped Grade III or IV aGvHD. The 100 day transplant-related mor-
tality was 1/3 (33%) and 4/6 (66%) in the RIC group and in the
myeloablative conditioning group, respectively. One patient died
of sinusoidal obstruction syndrome on day 20. The 100 day overall
survival (OS) in patients who did not achieve effective cytoreduction
was comparable to those with effective cytoreduction at 60% and
50%, respectively. The one year OS was 22%. One patient is alive
and disease-free with out GVHD at 58 months.
Our findings demonstrate that survival at 100 days and one year
was independent of clofarabine cytoreduction. These results suggest
that effective cytoreduction with clofarabine is not necessary for
a prolonged response in patients with refractory AML. The one-year
OS in this heavily pretreated refractory population is comparable to
published data. Treatment related mortality was high, particularly in
those patients who received myeloablative conditioning which is
attributable to infectious complications. However, clofarabine fol-
lowed by a RIC allogeneic transplant was tolerated and may be asso-
ciated with a prolonged response.
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DOUBLE TRANSPLANT OF UMBILICAL CORD BLOOD STEM CELL OF
UNRELATED DONORS IN THE TREATMENT OF PEDIATRIC PATIENTS
WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND REMISSION.
PILOT STUDY
Olaya-Vargas, A.1, Perez-Garcia, M.1, Gaytan-Morales, F.2, Del
Campo-Martinez, A.1, Aguilar, D.1 1National Pediatric Institute,
Mexico, DF, Mexico; 2Hospital Infantil de Mexico, Federico Gomez,
Mexico, DF, Mexico
Introduction: The possibility of successful transplantation of cord
blood decreases when cellular dose is low and the compatibility are
not match, so you have to look for options to improve the chances
of successful transplantation.
Material and Methods:We performed a pilot study comparing the
transplant that were performed with two units of umbilical cord
blood of unrelated donor in patients with ALL in second remission
and compared with a group of patients who were transplanted with
a single unit of umbilical cord blood, we evaluated the cell dose,
time of graft and overall survival and event-free survival between
both groups.
Results: Was included a total of 5 patients in the transplant group
with 2 units and 10 patients in the group with a single unit. Cell
dose for the first group was 5.3 x 10e6 of mononuclear cells and
the second group 3.5 x 10e6 mononuclear cells per kilogram of
body weight (p 5 0.16), in all cases histocompatibility was 4 / 6 for
the first group, second group compatibility was 4 / 6 in 5 cases, 5 /
6 in 4 and 6 / 6 in 1 case. Graft was achieved in 100% of patients
in group 1, group 2 graft failure was reported in 2 patients with graft
histocompatibility 4/6. The time of the grafting for the first group
was 17 days and for group 2 was 32 days (p 0.02), 4 of 5 patients
who were transplanted with 2 units of umbilical cord blood are alive
and disease free and in the second group only 5 of 10 patients are
alive and disease free at 12 month follow-up.
Conclusion: The Transplant 2 units of umbilical cord blood in this
pilot study demonstrated to be an appropriate option for improving
the performance of recovery time and better survival.
